Moreover, a high expression of S1PR4 for GBM patients and S1PR3 for LGG patients is correlated with poor prognosis, suggesting that targeting S1PR through an inhibitor like Fingolimod might be relevant in glioma. This evidence concerns the gene S1PR4 and glioblastoma.